GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: HR-20013 | HR20013 | Ritanine® (fosrolapitan + palonosetron)
fosrolapitant is an approved drug
Compound class:
Synthetic organic
Comment: Fosrolapitant (HR20013) is rapidly converted to rolapitant which is a selective NK1 receptor antagonist.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| China's NMPA approved a fixed-dose combination of fosrolapitant and palonosetron in May 2025; to prevent chemotherapy-induced nausea and vomiting [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05465681 | Study of HR20013 for Injection in Patients With Malignant Solid Tumors | Phase 1 Interventional | Fujian Shengdi Pharmaceutical Co., Ltd. | 2 | |
| NCT05509634 | Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors | Phase 3 Interventional | Fujian Shengdi Pharmaceutical Co., Ltd. | 3 | |